Spondyloarthritis

Upadacitinib achieved positive results from both Phase 3 SELECT-AXIS clinical trials, which focused on patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis.

The 2 studies focused on upadacitinib treatment for one group of patients with ankylosing spondylitis and another group of patients with non-radiographic axial spondyloarthritis.

Limited information is available on the overall disease burden of axial spondyloarthritis (axSpA) in women, as they are generally underrepresented in clinical studies.

“Many patients with axial spondyloarthritis who receive treatment still experience disease-related burdens in different aspects of health-related quality of life,” investigators stated.

“Understanding the role of ixekizumab will allow physicians to translate a higher Assessment of Spondyloarthritis International Society (ASAS) achievement to the improvements in the signs and symptoms reported by their patients,” investigators stated.

High levels of sedentary activity and low levels of physical activity found in patients with axSpA

"Physical activity and exercise have been shown to improve general well-being and reduce cardiovascular disease risk in the general population," investigators stated. "Despite these recommendations, studies show that levels of PA are reduced among patients with axial spondyloarthritis.”

The Epionics SPINE is an innovative tool to assess the spinal mobility of patients with axial spondyloarthritis.

Investigators from Turkey show how static foot posture in patients with rheumatic diseases can lead to impairment of physical function due enthesitis.

Atul Deodhar, MD, MRCP, discusses his recent study investigating the efficacy and safety of upadacitinib in active ankylosing Spondylitis, including study design, results, and its clinical significance.

Jeffrey Stark, MD, discusses the statement UCB issued endorsing the creation of a new sub-category (M.45A) for non-radiographical axial spondyloarthritis (nr-axSpA).

Rheumatology Network spoke with Jessica Walsh, MD, to discuss her study, “Patient perspectives of biologic treatments for axial spondyloarthritis: satisfaction, wear-off between doses, and use of supplemental medications."

Investigators discovered that women with axial spondyloarthritis (axSpA) have an overall higher disease burden and more peripheral manifestations when compared with men. They further theorized that awareness of these differences and the way the condition presents differently in both sexes may be used to more easily identify axSpA and improve disease management.

Artificial intelligence (AI) detected axial spondyloarthritis (axSpA) in radiographic scans of sacroiliac joints as accurately as human experts, shows a new study.

An analysis of patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with an elevated C-reactive protein (CRP) and/or evidence of sacroiliitis on magnetic resonance imaging (MRI) found that secukinumab (Cosentyx, Novartis) use resulted in numerically higher treatment response rates than placebo.

Back pain is the second leading symptom prompting a visit to a primary care physician. Here, we highlight a review of axial spondyloarthritis from Mayo Clinic Proceedings. The review aims to help primary care physicians detect this condition and know when to refer to a rheumatologist.

Despite major advances in axial spondyloarthritis and an increasing number of therapeutic options, questions remain related to the optimized treatment strategies and to the individual drug choice, according to a review published in Current Rheumatology Reports.

Patient assessments measured fatigue, disease activity, global spinal pain, and spinal pain at night.

Patients with axial spondyloarthritis who smoke may be more likely to have sacroiliac joint inflammation if they have a blue‐collar job or low education, according to a study recently published in Arthritis & Rheumatology. In this Q&A with study author Elena Nikiphorou, M.B.B.S./B.Sc., M.D.(Res), Consultant Rheumatologist at King's College Hospital in London, U.K.,we discuss the study and its findings.

Patients with axial spondyloarthritis may be more susceptible to higher disease activity if they are overweight or obese, according to a systematic review and meta-analysis published in RMD Open. In this Q&A with study author Jean Liew, M.D., of University of Washington in Seattle, we discuss the study and its significance.

French researchers writing in Arthritis and Rheumatology report that of 609 surveyed spondyloarthritis patients self-isolating at home due to COVID-19, most say their condition has progressed while in isolation and for some, the change has been considerable.

The approval is based on the phase 3 PREVENT trial, presented at the European E-Congress of Rheumatology 2020 (EULAR 2020) virtual meeting.

The increased cardiovascular disease risk in patients with ankylosing spondylitis is explained both by traditional  cardiovascular risk factors as well as the underlying chronic inflammatory process. However, this dual etiology is not adequately addressed in clinical practice, according to a presentation on June 3 at the European Congress of Rheumatology (EULAR) annual meeting.

Spondyloarthritis is associated with an increased risk of preterm births, small gestational age infants and elective cesarean section deliveries, according to study data presented on June 4 at the European Congress of Rheumatology (EULAR) annual meeting.

Study drug also recently showed promise in treating psoriatic arthritis.